Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

As Insurers Eye Private Credit, PCR Offers a Timely Opportunity

BY | ETF Database
7:18 am ET 07/27/26 | 5 VIEWS
  • Related Symbols
  • PCR
Institutional interest in private credit (PC) is surging. According to Marsh’s 2026 Global Insurance Investments Survey, 57% of insurers plan to increase their private credit allocations over the next 12 to 24 months, which constitutes a massive leap from just 32% the previous year. In particular, this demand is robust among large North American institutions that seek meaningful yield pickup compared to public market alternatives.Key Takeaways: Insurer demand for private credit is surging, with 57% of institutions planning to increase allocations despite widespread concerns over tighter spreads, rising defaults, and internal expertise gaps. PCR offers liquid access to private credit through BDCs and closed-end funds, effectively outsourcing complex asset selection. To address credit downside, PCR incorporates a built-in long/short equity swap hedge designed to protect capital against default cycles and spread compression. See More: Beyond Corporate Bonds: Enhance Income With Private CreditTurning Private Credit Fears Into OpportunityThe rush into private credit doesn’t come without its detractors. According to the Marsh Survey, two-thirds of insurers worry about tighter spreads and reduced illiquidity premiums. Additionally, 51% fear rising defaults, while only 30% feel they possess the internal expertise to invest confidently. This capability and risk-management gap is exactly where the Simplify VettaFi Private Credit Strategy ETF (PCR) comes into play. For both institutional and retail investors seeking private credit exposure without taking on unhedged downside risk, PCR offers a highly sophisticated, liquid alternative. PCR builds a core foundation in the asset class by investing in business development companies (BDCs) and publicly traded closed-end funds (CEFs). This structure immediately solves the expertise gap cited by 70% of insurers by outsourcing asset selection to seasoned portfolio managers who specialize in navigating private credit.Strategic, Built-In Hedging Within ETFMore importantly, PCR directly addresses institutional anxieties regarding default risk and tighter spreads. Unlike standard long-only private credit allocations, the ETF utilizes a proprietary long/short credit hedge driven by total return swaps on quality and junk equities. Because junk equities frequently act as a leading indicator for systemic credit deterioration, this built-in defensive overlay helps to insulate investors against the exact rising default cycles and widening spreads that insurers now fear. Ultimately, by wrapping an institutional-grade private credit strategy and an active risk hedge into a transparent, liquid ETF, PCR effectively democratizes a highly sought-after asset class. The fund also answers the market’s growing call for defensive capital preservation in today’s uncertain fixed income environment. For more news, information, and analysis, visit the Institutional Income Strategies Content Hub. VettaFi LLC (“VettaFi”) is the index provider for PCR, for which it receives an index licensing fee. However, PCR is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of PCR.

More Commentary

As Small-Caps Rise, Pair These ETFs for Value, Growth Views
BY | ETF Database
8:25 am ET 07/27/26 | 1 VIEW
Analysts Growing Bullish on AMD; AMUU May Be Worth a Trade
BY | ETF Database
7:26 am ET 07/27/26 | 6 VIEWS
Thornburg's THOR Skips the Valuation Rally
BY | ETF Database
6:32 am ET 07/27/26 | 9 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.